GOP's new Obamacare strategy: death by a thousand cuts

6 October 2017
protest_healthcare_senate_big

Yet another congressional push to repeal and replace the Affordable Care Act has failed as, for a second time, Republicans opted to withdraw proposals rather than face the humiliation of defeat.

Lawmakers have now missed the opportunity to use a legislative route known as budget reconciliation to avoid a Democratic filibuster, making the odds against ‘repeal and replace’ insurmountable.

The end of the Graham-Cassidy bill, which would have prevented the expansion of Medicaid eligibility and converted many provisions into block grants for states, must therefore surely be the final nail in the coffin for Trumpcare, at least in this political cycle.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical